Immutep Ltd · ASX:IMM
Immutep — Shareholder Meeting (July 2021)
24 slides from Immutep's shareholder meeting presentation, Jul 26, 2021
Slide 1: The global leader in developing LAG-3 therapeutics
For personal use only The global leader in developing LAG-3 therapeutics (ASX: IMM, NASDAQ: IMMP) Extraordinary General Meeting CEO Presentation 26 July 2021
Slide 2: Notice: Forward Looking Statements
Notice: Forward Looking Statements For personal use only The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further
Slide 3: Overview
Overview For personal use only Immutep is an innovative biotechnology Collaboration deals company developing novel executed with industry leaders immunotherapies for cancer and autoimmune disease Global leadership position in LAG-3 with 4 product candidates in immuno-oncology and autoimmune disease
Slide 4: LAG-3 Overview - Landscape
For personal use only LAG-3 Overview - Landscape-
Slide 5: LAG-3 Acceleration & Validation
LAG-3 Acceleration & Validation For personal use only LAG-3 Scientific Publications LAG-3 is an exciting and promising immune checkpoint for cancer treatment Accelerating interest in LAG-3: • Over 900 scientific publications dealing with LAG-3 • More than 80 clinical trials evaluating 19 LAG-3 produ
Slide 6: Immutep's LAG-3 Trial Pipeline
Immutep’s LAG-3 Trial Pipeline* Commercial Program Preclinical Phase I Phase II Late Stage(5) Market Size(6) Rights For personal use only Metastatic Breast Cancer (Chemo – IO) US$29.9 billion AIPAC Head and Neck Squamous Cell Carcinoma (IO – IO) (1b) TACTI-003 US$1.9 billion Head and Neck Squamous C
Slide 7: Immutep Out-Licensed LAG-3 Trial Pipeline
Immutep Out-Licensed LAG-3 Trial Pipeline* For personal use only Commercial Program Preclinical Phase I Phase II Late Stage(1) Updates Rights/Partners Solid Tumors + Blood Cancer (IO-IO Combo) Triple Negative Breast Cancer (Chemo-IO Combo) Novartis currently has five Oncology Global Rights clinical
Slide 8: TACTI-002 (Phase II) Design & Status
TACTI-002 (Phase II) Design & Status TACTI-002: Two ACTive Immunotherapeutics in NSCLC and HNSCC For personal use only UNSELECTED FOR PD-L1 In collaboration with PART A: S 1ST LINE MET. NSCLC C R PART B: COMBINED E ORR, PFS, OS, PK, 2ND LINE MET. NSCLC, IMMUNOTHERAPY E PEMBROLIZUMAB + EFTI FOR 12 bi
Slide 9: TACTI-002 Results: 1st line NSCLC (Part A)
TACTI-002 Results(1) 1st line NSCLC (Part A) • PD-L1 distribution as expected (~70% with < 50% PD-L1 expression) → PD-L1 all comer trial For personal use only • Patients are typical NSCLC 1st line pts Local Read Blinded Read Baseline parameters N (%) Best overall response, iRECIST, N = 36 (investiga
Slide 10: TACTI-002 Results: 1st line NSCLC stage 1 & 2
TACTI-002 Results(1) 1stPart lineA* NSCLC (Part - 1st line A) NSCLC stage 1 & 2 Part A* - 1st line NSCLC (stage 1+2) For personal use only 120 Best response: iUPD/iCPD 100 Best response: 100 % change compared to baseline iSD iUPD/iCPD 75 Best % change from baseline 60 iPR iSD 40 50 iPR iCR iCR 20 25
Slide 11: TACTI-002 Results: 2nd line HNSCC (Part C)
TACTI-002 Results(1) 2nd line HNSCC (Part C) • 2nd line treatment for patients after platinum therapy. PD-L1 all comer population For personal use only • Doubling the ORR compared to historical pembro mono results with 13.5% Complete Responses Baseline parameters (N=39) N (%) Best overall response*,
Slide 12: TACTI-002 Results: 2nd line HNSCC Stage 1 & 2
TACTI-002 Results(1) 2nd line HNSCC (Part C) Part C* - 2nd line HNSCC Stage 1 & 2 Part C* - 2nd line HNSCC Stage 1&2 For personal use only 100 100 Best response: Best response: iUPD/iCPD % change compared to start of therapy 80 iUPD/iCPD 75 iSD Best % change from baseline 60 iSD iPR iPR 50 iCR 40 iC
Slide 13: TACTI-002 Results: 2nd line HNSCC PFS
TACTI-002 Results(1) 2nd line HNSCC (Part C) PFS 2nd line PlotHNSCC For personal use only Kaplan-Meier PFS* 100 Probability of Survival 90 CPS >=1 (n=24) 80 70 unselected for PD-L1 (n=37) 60 50 40 30 20 10 0 0 6 12 18 24 months Overall population (unselected for PD-L1) Selected for PD-L1 expression,
Slide 14: INSIGHT-004 (Stratum D) Results
INSIGHT-004 (Stratum D) Results(1) For personal use only Efficacy Best overall response (RECIST 1.1) • 5/12 (42%) with partial responses in different indications: • 1st line MSI high colorectal cancer; 1st line pleural mesothelioma; after radiochemo in squamous anal cell; pre-treated squamous cervic
Slide 15: IMP761 a Potential Game Changer for Autoimmune Diseases
IMP761 a Potential Game Changer for Autoimmune Diseases For personal use only Current autoimmune drugs fight the symptoms, treating general inflammation (corticoids, methotrexate, anti-TNF-α, -IL-6, -IL-17, - IL-23 mAbs) IMP761 potentially fights the cause, treating the disease process by silencing
Slide 16: New Efti Studies - TACTI-003, INSIGHT-005 & INSIGHT-003
For personal use only New Efti Studies - TACTI-003, INSIGHT-005 & INSIGHT-003 -
Slide 17: Positive data driving expansion of clinical program
Positive data driving expansion of clinical program For personal use only With the ongoing strength of data reported at leading conferences SITC 2020; SABCS 2020; ASCO 2021), Immutep plans to expand and advance its clinical portfolio(1) : Manufacturing New Phase III Registration Other Trials New Pha
Slide 18: TACTI-003 Trial in 1st line HNSCC
TACTI-003 Trial in 1st line HNSCC Current Design + Status For personal use only In collaboration with Design: • Randomised study with ORR as primary endpoint • Sites worldwide (AU, US, Europe) • Approx. 154 pts: either to be randomized to have sufficient pts. in each group or in an experimental arm
Slide 19: INSIGHT Platform Trial: INSIGHT-005 study arm
INSIGHT Platform Trial in Solid Tumours INSIGHT-005 study arm (Stratum E): Efti + Bintrafusp Alfa combo For personal use only To evaluate the feasibility and safety of combined treatment with bintrafusp alfa (M7824) and eftilagimod alpha. Institut für Klinisch-Onkologische Forschung In collaboration
Slide 20: INSIGHT Platform Trial: INSIGHT-003 study arm
INSIGHT Platform Trial in Solid Tumours New INSIGHT-003 study arm (Stratum C): Efti + anti-PD-1 + chemo For personal use only First evaluation of efti in a triple combination therapy Phase I study INSIGHT-003 is a new stratum of the investigator-initiated phase I trial, INSIGHT • Expansion into trip
Slide 21: Corporate Snapshot & Outlook
For personal use only Corporate Snapshot & Outlook
Slide 22: Corporate Snapshot
Corporate Snapshot For personal use only IMM (ASX) Ticker symbols IMMP (NASDAQ) Securities on issue(1) (post transaction) ~ 850.92 million ordinary shares Proforma cash balance(2) (post transaction) ~ A$114.03 million (US$85.73 million) Market Cap(3) ~ A$425.46 million (US$311.61 million) (post tran
Slide 23: 2021/2022 News Flow
2021/2022 News Flow* For personal use only H1 2021 H2 2021 2022 ✓ Fast Track designation granted for efti in 1st line HNSCC from US FDA ❑ Final data from AIPAC: 2nd OS follow up in H2 2021 ✓ Data from TACTI-002 & final data from INSIGHT- ❑ Start & ongoing recruitment of new randomised 004 at ASCO tr
Slide 24: Thank You
For personal use only Thank You